- Piramal Pharma Solutions has successfully developed, scaled up, and commercialised a tablet-in-capsule drug delivery system at its facilities in Pithampur and Ahmedabad, India.
- The technology enables flexible dosing and modified-release oral therapies and is now available as part of the company’s CDMO and contract manufacturing services.
Piramal Pharma Solutions has announced the successful development, scale-up, and commercialisation of a tablet-in-capsule drug delivery system at its drug product manufacturing sites in Pithampur and Ahmedabad, India. The work was completed as part of the company’s contract development and manufacturing services and supports flexible dosing options for oral drug therapies, including modified-release formulations.
The project was initiated at Piramal Pharmaceutical Development Services in Ahmedabad and achieved a full technology transfer to the commercial manufacturing site in Pithampur within five months. This included the development of three tablets designed to be encapsulated within a single capsule shell.
According to the company, integrated programme management and coordination between development, technology transfer, quality control, and validation teams at both sites supported a seamless transition from development to commercial scale. These efforts ensured product safety and efficacy during scale-up.
Tablet-in-capsule technology differs from traditional capsule formats by allowing separate tablets or minitablets to be placed into a single capsule. This enables distinct release profiles through tailored coatings and allows incompatible active ingredients to be combined in one dosage form, with the aim of reducing dosing frequency and supporting patient adherence.
“By enabling dual actives in the same capsule or dual-release profiles within a single capsule, our tablet-in-capsule technology provides unmatched dosing flexibility and release control.”
Brad Gold, Ph.D., Head of Global Formulations R&D at Piramal Pharma Solutions.
The company said the technology is now part of its formulation offering as a CDMO providing contract manufacturing services for oral drug products.
